Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) Research & Development (2016 - 2025)

Moleculin Biotech's Research & Development history spans 10 years, with the latest figure at $5.1 million for Q4 2025.

  • Quarterly results put Research & Development at $5.1 million for Q4 2025, up 14.86% from a year ago — trailing twelve months through Dec 2025 was $15.9 million (down 10.37% YoY), and the annual figure for FY2025 was $15.9 million, down 10.37%.
  • Research & Development for Q4 2025 was $5.1 million at Moleculin Biotech, up from $3.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $6.6 million in Q4 2023 to a low of $3.0 million in Q2 2021.
  • The 5-year median for Research & Development is $4.1 million (2021), against an average of $4.3 million.
  • The sharpest move saw Research & Development soared 78.0% in 2021, then tumbled 45.01% in 2023.
  • Year by year, Research & Development stood at $3.2 million in 2021, then soared by 31.42% to $4.2 million in 2022, then skyrocketed by 58.74% to $6.6 million in 2023, then crashed by 32.83% to $4.5 million in 2024, then increased by 14.86% to $5.1 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $5.1 million, $3.7 million, and $3.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.